Home » Stocks » CNSP

CNS Pharmaceuticals, Inc. (CNSP)

Stock Price: $1.72 USD 0.00 (0.00%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
After-hours: $1.82 +0.10 (5.81%) Jul 28, 6:03 PM
Market Cap 43.37M
Revenue (ttm) n/a
Net Income (ttm) -11.10M
Shares Out 25.36M
EPS (ttm) -0.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $1.72
Previous Close $1.72
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.71
Day's Range 1.68 - 1.75
Day's Volume 208,625
52-Week Range 1.62 - 4.46

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

These penny stocks pushed up in recent trading; are they worth watching? The post Best Penny Stocks to Buy Right Now?

Other stocks mentioned: MTSL, TBLT
2 weeks ago - PennyStocks

HOUSTON, July 1, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

3 weeks ago - PRNewsWire

HOUSTON, June 29, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

4 weeks ago - PRNewsWire

HOUSTON, June 17, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

1 month ago - PRNewsWire

CNS Pharmaceuticals Inc (NASDAQ: CNSP) has opened enrollment for its Phase 2 study evaluating its lead candidate, Berubicin, for recurrent Glioblastoma Multiforme (GBM). The company intends to enroll ap...

2 months ago - Benzinga

HOUSTON, May 19, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc.  (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and...

2 months ago - PRNewsWire

HOUSTON, May 14, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

2 months ago - PRNewsWire

HOUSTON, May 11, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

2 months ago - PRNewsWire

HOUSTON, March 15, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc.  (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary a...

4 months ago - PRNewsWire

CNS Pharmaceuticals Inc's (NASDAQ: CNSP) partner WPD Pharmaceuticals received a favorable opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland, for its planned upcoming Beru...

5 months ago - Benzinga

HOUSTON, Feb. 18, 2021 /PRNewswire/ -- WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ("WPD") and CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), biopharmaceutical companies specializing in ...

5 months ago - PRNewsWire

Looking for penny stocks to buy? Click for seven that are hot right now and should continue to rise in the future.

Other stocks mentioned: AMRS, CYRN, MREO, NGD, RARE, XELA
6 months ago - InvestorPlace

HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc . (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and m...

7 months ago - GlobeNewsWire

HOUSTON, Dec. 18, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

7 months ago - PRNewsWire

HOUSTON, Dec. 17, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

7 months ago - PRNewsWire

HOUSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and me...

8 months ago - GlobeNewsWire

HOUSTON, Oct. 9, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and m...

9 months ago - PRNewsWire

HOUSTON, Sept. 24, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel t...

10 months ago - GlobeNewsWire

HOUSTON, Sept. 11, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.

10 months ago - PRNewsWire

Houston, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of n...

10 months ago - GlobeNewsWire

HOUSTON, Aug. 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.

11 months ago - PRNewsWire

HOUSTON, Aug. 20, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.

11 months ago - PRNewsWire

HOUSTON, July 22, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

1 year ago - PRNewsWire

HOUSTON, July 8, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and m...

1 year ago - PRNewsWire

HOUSTON, May 28, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and m...

1 year ago - PRNewsWire

HOUSTON, May 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

1 year ago - PRNewsWire

HOUSTON, May 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

1 year ago - PRNewsWire

Moleculin Biotech Inc. MBRX, -1.83% and CNS Pharmaceuticals Inc. CNSP, -3.83% said Monday their shares remain halted on Nasdaq with the exchange seeking additional information from each company.

Other stocks mentioned: MBRX
1 year ago - Market Watch

HOUSTON, May 18, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

1 year ago - PRNewsWire

Moleculin Biotech Inc. MBRX, -1.83% and CNS Pharmaceuticals Inc. CNSP, -3.83% said Monday they did not solicit or have any advance knowledge about claims made by third parties about drug candidate WP112...

Other stocks mentioned: MBRX
1 year ago - Market Watch

CNS Pharmaceuticals (NASDAQ: CNSP) shares are trading higher on Monday. The company announced that independent research from the University of Frankfurt showed that an active compound in WP1122 complete...

1 year ago - Benzinga

Nano-cap biotech CNS Pharmaceuticals Inc (NASDAQ: CNSP), which develops treatments for cancers of the brain and central nervous systems, said Monday that it has struck an agreement with Canada's WPD Pha...

1 year ago - Benzinga

CNS Pharmaceuticals, Inc. (CNSP) Management on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About CNSP

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based i... [Read more...]

Industry
Biotechnology
IPO Date
Nov 8, 2019
Stock Exchange
NASDAQ
Ticker Symbol
CNSP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CNSP stock is "Buy." The 12-month stock price forecast is 8.33, which is an increase of 384.30% from the latest price.

Price Target
$8.33
(384.30% upside)
Analyst Consensus: Buy